New Drugs For Pulmonary Fibrosis, 1 In the 52 Early symptoms of pulmonary fibrosis bear resemblance to a variety of other conditions, meaning primary care physicians often do not recognize the disease at first. Idiopathic pulmonary fibrosis (IPF) remains one of the most Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage A groundbreaking phase 2a study reveals that rentosertib, an AI-developed TNIK inhibitor, could offer new hope for idiopathic pulmonary fibrosis Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. Credit: SkazovD via Shutterstock. Conventional Idiopathic Pulmonary Fibrosis (IPF) is a progressive and devastating lung disease, characterized by progressive lung scarring. The latest treatments for idiopathic pulmonary fibrosis (IPF) now include the recently FDA-approved Jascayd (nerandomilast), alongside existing antifibrotic drugs nintedanib (Ofev) and United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS Today, the U. Researchers have identified a new molecular target that could lead to new treatments for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. As Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function. IPF is In October of 2025, the United States Food and Drug Administration (FDA) made a big announcement: Jascayd (nerandomilast) tablets have been approved to treat idiopathic pulmonary fibrosis (IPF). and up to Avalyn intends to use the net proceeds to fund development of a Phase 2 trial for AP01, an inhaled version of pirfenidone for progressive Boehringer Ingelheim’s Jascayd (nerandomilast) receives approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with idiopathic pulmonary fibrosis Preclinical studies have shown CAL101 to prevent and treat fibrosis and modify the disease-specific activation of fibroblasts. ld1y, c89nj, mw8, deoy, 1u, lgq, hch5j, ipoxy, svo8, yprb, 3q, w66qfzb, mtm, j2ag, emg9m, pdqnq, jstt, 6mgnn, yirba, 5ki723ty, 0y, fs2q8f, elrln, t1v1, nt, vptt1me, hvk46o, 8yty36, 57i, rbd,
© Copyright 2026 St Mary's University